Dementia: Module 1

Recognition and management of mild cognitive impairment

CPD QUESTIONNAIRE

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. (Online) _____

(Signature of healthcare professional)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail			

1. The proportion of people younger than 75 years who will not develop dementia is:

☐ **A** 40% ☐ **B** 50% ☐ **C** 60% ☐ **D** 70%

2. Which of the following is not a risk factor for age-related cognitive decline?

☐ **A** Depression ☐ **B** Atrial fibrillation
☐ **C** Diabetes mellitus ☐ **D** Longer duration of education

3. Which of the following vitamins may be protective against age-related cognitive decline?

☐ **A** B ☐ **B** C ☐ **C** D ☐ **D** A

4. Which of the following scores on the MMSE is most probably indicative of MCI?

☐ **A** 27-30 ☐ **B** 24-27 ☐ **C** 16-23 ☐ **D** 12-18

5. The duration of treatment with HT is usually not longer than:

☐ **A** One year ☐ **B** Two years ☐ **C** Eight years ☐ **D** 12 years

6. NSAIDs may be protective against MCI if used for longer than:

☐ **A** Three months ☐ **B** Six months ☐ **C** One year ☐ **D** 2-3 years

7. Cognitive deterioration is associated with a progressive loss of:

☐ **A** Cholinergic neurones ☐ **B** Dopaminergic neurones
☐ **C** Glutaminergic neurones ☐ **D** GABAergic neurones

8. Memantine is a:

☐ **A** Kainate receptor antagonist ☐ **B** AMPA receptor antagonist
☐ **C** NMDA receptor antagonist ☐ **D** Glutamate delta receptor antagonist

9. The starting dose of donepezil is:

☐ **A** 5mg in the morning ☐ **B** 10mg in the evening
☐ **C** 2.5mg in the evening ☐ **D** 2.5mg in the morning and evening

10. Galantamine has activity at:

☐ **A** Kainate receptors ☐ **B** AMPA receptors
☐ **C** NMDA receptors ☐ **D** Nicotinic receptors

11. In patients with MCI, the efficacy of memantine may be increased by combining it with:

☐ **A** An acetylcholinesterase inhibitor ☐ **B** An antipsychotic
☐ **C** An antidepressant ☐ **D** A mood stabiliser

12. Elderly patients receiving a psychotropic medication typically require:

☐ **A** Double the usual adult dose ☐ **B** The usual adult dose
☐ **C** One-half to one-third of the usual adult dose ☐ **D** One-quarter of the usual adult dose

13. Which antidepressant is preferable for an elderly patient with MCI?

☐ **A** Venlafaxine ☐ **B** Duloxetine
☐ **C** A tricyclic antidepressant ☐ **D** Mirtazapine

14. Which of the following is the most appropriate combination of antipsychotics for an elderly patient with MCI?

☐ **A** Olanzapine plus risperidone ☐ **B** Olanzapine plus chlorpromazine plus quetiapine
☐ **C** Haloperidol plus chlorpromazine plus quetiapine ☐ **D** Risperidone plus quetiapine

15. In an elderly patient with MCI and a psychotic episode, the most appropriate drug choice for acute sedation is:

☐ **A** Clonazepam ☐ **B** Lorazepam ☐ **C** Diazepam ☐ **D** Chlordiazepoxide

© 2020 deNovo Medica